Supplementary Table S10. Demographics and tumor type of the 575 patient anti-PD-(L)1 monotherapy self-reported race validation cohort and the non-European subset

Variable	Statistic	Anti-PD-(L)1 cohort n (%)	Non-European Subgroup n (%)
Age (yrs)	n	575	47
	median (IQR)	66 (59-75)	64 (50.5-71)
Sex	n (%)		
Female		246 (42.8%)	19 (40.4%)
Male		329 (57.2%)	28 (59.6%)
Race	n (%)		
Asian		3 (0.5%)	3 (6.4%)
Black or African American		30 (5.2%)	30 (63.8%)
Other		14 (2.4%)	14 (29.8%)
Unknown, Missing, or Not Reported		204 (35.5%)	
White or Caucasian		369 (64.2%)	
Ethnicity	n (%)		
Hispanic or Latino		7 (1.2%)	4 (8.5%)
Not Hispanic or Latino		364 (63.3%)	39 (83.0%)
Unknown, Missing, or Not Reported		204 (35.5%)	4 (8.5%)
Anti-PD-(L)1 line of therapy	n (%)		
1		393 (68.3%)	33 (70.2%)
2		126 (21.9%)	9 (19.1%)
3+		56 (9.7%)	5 (10.6%)
Anti-PD-(L)1 therapy type	n (%)		
pembrolizumab		275 (47.8%)	33 (70.2%)
other anti-PD-(L)1 therapy		300 (52.2%)	14 (29.8%)
Primary Tumor Type	n (%)		
Adrenocortical Carcinoma		1 (0.2%)	1 (2.1%)
Ampullary Carcinoma		1 (0.2%)	
Appendiceal Cancer		1 (0.2%)	
Bladder Cancer		45 (7.8%)	3 (6.4%)
Breast Cancer		17 (3.0%)	2 (4.3%)
Cancer of Unknown Primary		53 (9.2%)	4 (8.5%)
Cervical Cancer		7 (1.2%)	
Colorectal Cancer		12 (2.1%)	2 (4.3%)
Endometrial Cancer		4 (0.7%)	
Esophagogastric Cancer		22 (3.8%)	1 (2.1%)
Glioma		3 (0.5%)	
Head and Neck Cancer		38 (6.6%)	7 (14.9%)
Hepatobiliary Cancer		13 (2.3%)	3 (6.4%)
Lymphoma		2 (0.3%)	
Melanoma		87 (15.1%)	1 (2.1%)
Mesothelioma		2 (0.3%)	1 (2.1%)
Non-Small Cell Lung Cancer		144 (25.0%)	16 (34.0%)
Other Cancer		8 (1.4%)	2 (4.3%)
Ovarian Cancer		4 (0.7%)	
Pancreatic Cancer		4 (0.7%)	1 (2.1%)
Penile Cancer		1 (0.2%)	
Prostate Cancer		2 (0.3%)	
Renal Cell Carcinoma		38 (6.6%)	1 (2.1%)
Salivary Gland Cancer		2 (0.3%)	
Sarcoma		13 (2.3%)	2 (4.3%)
Skin Cancer, Non-Melanoma		19 (3.3%)	
Small Cell Lung Cancer		22 (3.8%)	
Thymic Tumor		1 (0.2%)	
Thyroid Cancer		1 (0.2%)	
Vaginal Cancer		4 (0.7%)	

Demographics and tumor types for all included patients including age (in years), sex, self reported race, self reported ethnicity, and the anti-PD-(L)1 line of systemic therapy. The StrataNGS CGP assigned primary tumor type for each patient is provided. n= sample size, %= percentage, IQR = interquartile range.